Table 3 Included participants in EPAD Longitudinal cohort study per recruitment setting
| Â | Toulouse Registry | ALFA Study | Generation Scotland | pilotHO.nl | ||||
|---|---|---|---|---|---|---|---|---|
CSF Aβ +ve | CSF Aβ normal | CSF Aβ +ve | CSF Aβ normal | CSF Aβ +ve | CSF Aβ normal | CSF Aβ +ve | CSF Aβ normal | |
n | 23 | 41 | 36 | 88 | 22 | 39 | 26 | 49 |
Age, year | 71 (5) | 67 (8)^ | 64 (6) | 64 (5) | 71 (3) | 67 (5)# | 68 (6) | 66 (7) |
Male, n (%) | 4 (17%) | 17 (41%) | 23 (64%) | 41 (47%) | 14 (61%) | 23 (57%) | 14 (52%) | 19 (37%) |
MMSE (30–0) | 28.0 (2.1) | 28.8 (1.7) | 28.6 (1.1) | 28.7 (1.6) | 28.1 (1.6) | 28.8 (1.4) | 28.4 (1.5) | 29.1 (1.3) |
CDR-SOB (0–18) | 0.74 (0.7) | 0.34 (0.5)^ | 0.10 (0.3) | 0.05 (0.2) | 0.15 (0.3) | 0.06 (0.2) | 0.06 (0.2) | 0.02 (0.1) |
CSF Aβ1–42, pg/mL | 756 (195) | 1613 (361)# | 823 (191) | 1696 (519)# | 748 (251) | 1769 (411)# | 846 (217) | 1788 (443)# |
CSF P-tau, pg/mL | 29 (15) | 18 (4.9)$ | 21 (15) | 17 (7) | 19 (9) | 21 (12) | 21 (10) | 17 (5) |
CSF T-tau, pg/mL | 305 (125) | 210 (53)$ | 223 (132) | 209 (79) | 211 (81) | 249 (115)* | 240 (101) | 206 (58) |
MTA (0–4) | 0.4 (0.5) | 0.2 (0.4) | 0.2 (0.4) | 0.1 (0.3) | 0.4 (0.6) | 0.1 (0.4) | 0.2 (0.4) | 0.2 (0.4) |
Fazekas (0–3) | 1.1 (0.7) | 0.8 (0.7) | 1 (0.6) | 0.8 (0.6) | 1.1 (0.9) | 0.7 (0.7)^ | 0.9 (0.8) | 0.9 (0.7) |